2023-05-11 17:00:02 ET
- VYNE Therapeutics press release ( NASDAQ: VYNE ): Q1 GAAP EPS of -$1.74 beats by $0.87 .
- Revenue of $0.1M (-44.4% Y/Y).
- Research and development expenses . VYNE's research and development expenses for the quarter ended March 31, 2023 were $2.7 million,
- Net (loss) income. Net loss and net loss per share for the quarter ended March 31, 2023 was $5.6 million and $1.74, respectively, compared to net income and net income per share of $4.7 million and for the comparable period in 2022,
For further details see:
VYNE Therapeutics GAAP EPS of -$1.74 beats by $0.87, revenue of $0.1M